Table 3. Univariate analysis of PFS.
| Characteristic | HR (95% CI) | p value |
|---|---|---|
| Age | ||
| <60 | 1 | 0.021 |
| ≥60 | 1.68(1.08–2.60) | |
| Breast or OC positive family history | ||
| No | 1 | 0.983 |
| Yes | 1.01 (0.63–1.61) | |
| Stage | ||
| I–II | 1 | 0.696 |
| III–IV | 1.14 (0.58–2.23) | |
| Histology | ||
| High grade serous | 1 | 0.008 |
| Others | 0.14 (0.03–0.61) | |
| Surgery | ||
| Primary cytoreduction | 1 | 0.409 |
| Interval cytoreduction | 1.16 (0.81–1.67) | |
| Residual disease after primary surgery | ||
| primary surgery | ||
| ≤10 mm | 1 | 0.827 |
| >10 mm | 1.03 (0.78–1.36) | |
| PFI before bevacizumab | ||
| 6–12 months | 1 | 0.044 |
| ≥12 months | 0.63 (0.40–0.99) | |
| Treatment | ||
| CT alone | 1 | 0.225 |
| CT + bevacizumab | 0.77 (0.50–1.12) | |
| Number of previous treatment lines | ||
| 1 | 1 | 0.264 |
| >1 | 1.30 (0.82–2.04) | |
| CCNE1 overexpression | ||
| <2 | 1 | 0.069 |
| ≥2 | 1.77 (0.96–3.27) | |
PFI, Platinum free interval